220913-43-9

Basic information

• Product Name: TERT-BUTYL 4-AMINO-2-FLUOROPHENYLCARBAMATE
• Synonyms: TERT-BUTYL 4-AMINO-2-FLUOROPHENYLCARBAMATE;(4-Amino-2-fluoro-phenyl)-carbamic acid tert-butyl ester
• CAS NO: 220913-43-9
• Molecular Formula: C₁₁H₁₅FN₂O₂
• Molecular Weight: 226.25
• Mol File: 220913-43-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 4-AMINO-2-FLUOROPHENYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-AMINO-2-FLUOROPHENYLCARBAMATE(220913-43-9)
• EPA Substance Registry System: TERT-BUTYL 4-AMINO-2-FLUOROPHENYLCARBAMATE(220913-43-9)

Safety Data

• Hazardous Substances Data: 220913-43-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-AMINO-2-FLUOROPHENYLCARBAMATE is used as a building block for the synthesis of various drugs for its versatile reactivity and stability.
Used in Antiviral Applications:
TERT-BUTYL 4-AMINO-2-FLUOROPHENYLCARBAMATE is used as a key component in the development of antiviral agents, contributing to the creation of effective treatments against viral infections.
Used in Antibacterial Applications:
TERT-BUTYL 4-AMINO-2-FLUOROPHENYLCARBAMATE is used as a component in the synthesis of antibacterial drugs, aiding in the fight against bacterial infections.
Used in Anticancer Applications:
TERT-BUTYL 4-AMINO-2-FLUOROPHENYLCARBAMATE is used in the production of anticancer agents, playing a role in the development of treatments for various types of cancer.

Upstream product

• 369-35-7 2-fluoro-4-nitroaniline 
• 220913-42-8 tert-butyl (2-fluoro-4-nitrophenyl)carbamate 
• 658700-15-3 tert-butyl N-(3-fluoro-4-nitrophenyl)carbamate 
• 2369-13-3 3-fluoro-4-nitroaniline 

Relevant articles and documents

ISOTHIOCYANATE-ANDROGEN RECEPTOR INHIBITOR CONJUGATES FOR APOPTOSIS AND/OR FERROPTOSIS INDUCTION IN CANCER CELLS

Isothiocyanate (ITC)-androgen receptor (AR) inhibitor conjugates for apoptosis induction in cancer cells are described. The conjugates can have electrophilicity blocked with an agent such as N-acetyl cysteine. When administered in combination with a glutathione (GSH)-depleting agent, the conjugates result in ferroptosis of cancer cells.

ALLOSTERIC INHIBITOR OF WEE1 KINASE

Disclosed is a method for selecting a cancer therapeutic for a patient that involves assaying a tumor biopsy sample from the subject to detect PAXIP1 expression, and selecting a WEE1 inhibitor as the cancer therapeutic if PAXIP1 is detected in the tumor biopsy sample.

Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer

A series of novel, highly potent, selective CDK9 inhibitors with cancer stem cells (CSCs) inhibition activity were designed and synthesized for non-small-cell lung cancer (NSCLC) therapy. Structure-activity relationship analysis based on enzymatic and cellular activities led to the discovery of a promising inhibitor 21e. 21e potently inhibited CDK9 with IC50 value of 11 nM and suppressed the stemness properties of NSCLC effectively. It could decrease the stemness phenotypes of NSCLC cells, including tumor sphere formation, side-population and stemness markers abundance. 21e displayed good selectivity over the CDK family kinases and kinase profiling assay against 381 kinases. In addition, 21e inhibited cell proliferation, colony-formation, and cell cycle progression and induced apoptosis in NSCLC. In H1299 xenograft mouse model, a once-daily dose of compound 21e at 20 mg/kg significantly suppressed the tumor growth without obvious toxicity. Studies of mechanisms of action indicated that 21e efficiently inhibited CDK9 signaling pathway and stemness both in vitro and in vivo. Collectively, 21e as a novel CDK9 inhibitor with CSCs inhibition properties could be a promising agent for the treatment of NSCLC.

Camptothecin analogs and methods of preparation thereof

A compound and a method of synthesizing a compound having the following general formula (1): wherein R1 and R2 are independently the same or different and are hydrogen, an alkyl group, an alkenyl group, a benzyl group, an alkynyl group, an alkoxy group, a

Camptothecin analogs and methods of preparation thereof

The present invention provides generally a compound having the following general formula (1): wherein R1 and R2 are independently the same or different and are hydrogen, an alkyl group, an alkenyl group, a benzyl group, an alkynyl group, an alkoxyl group,